Genovate Biotechnology CoROCO:4130 +1.59%68 OCF Margin % is 14.18% as of Dec. 2025, which is 39% above its 10-year median of 10.17. GuruFocus rates ROCO:4130 with a GF Score™ of 68/100 and a GF Value™ of NT$22.16 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Genovate Biotechnology Co ranks better than 75.39% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4130 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co (ROCO:4130) has a OCF Margin % of 14.18% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Genovate Biotechnology Co and its competitors. This is 39% above median its historical median of 10.17. According to the industry distribution chart, Genovate Biotechnology Co ranks #236 out of 959 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Genovate Biotechnology Co's OCF Margin % too high?
Genovate Biotechnology Co's current OCF Margin % of 14.18% is 39% above median its 10-year median of 10.17. Based on the distribution chart, Genovate Biotechnology Co ranks #236 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #236 out of 959 companies for OCF Margin %. This places Genovate Biotechnology Co in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current OCF Margin % is 14.18%, which is 39% above median its own 10-year median of 10.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.16, compared to a current price of NT$25.50 — trading 15.1% above its estimated fair value. The current OCF Margin % is 14.18%, which is 39% above median its 10-year median of 10.17. Genovate Biotechnology Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current OCF Margin % is 14.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$25.50 is trading 15.1% above its estimated GF Value™ of NT$22.16.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
OCF Margin %: 14.18% (39% above median its 10-year median of 10.17)
GF Value™: NT$22.16 vs. price of NT$25.50 (15.1% above fair value)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
68GF Score
Get the complete analysis for ROCO:4130
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
